18 results
Familial Dyslipidemias

 • Hyperchylomicronemia
 • Familial hypercholesterolemia
 • Dysbetalipoproteinemia
 • Hypertriglyceridemia

Sarah Lyon @sarahthelyon

#Familial #Dyslipidemias #lipidemia #cardiology
Familial Dyslipidemias ... #Familial #Dyslipidemias ... #lipidemia #cardiology
Atorvastatin. HMG-CoA reductase inhibitor (statin) for dyslipidemia and MI/stroke prevention. 2nd most prescribed drug in the
inhibitor (statin) for dyslipidemia
Adverse Effects of Antipsychotic Medications - Comparison Table

First Generation: chlopromazine, haloperidol, fluphenazine 
Second Generation: aripirazole, asenapine,
Effects: EPS/TD, Dyslipidemia
NAFLD / NASH Progression Timeline
Healthy Liver → NAFLD/NASH → 0.25-3.2%/year → Cirrhotic NASH → 0.3-2.6%/year →
hypertension, Diabetes, Dyslipidemia
Risk factors for atherosclerosis

Modifiable risk factors:
 - Dyslipidemia (elevated LDL, decreased HDL)
 - Tobacco smoking
 -
risk factors: - Dyslipidemia
Health risks of obesity

Greatly increased risk (RR >3):
 - Mortality (BMI >30) 
 - Type 2
bladder disease - Dyslipidaemia
Abnormal Lipid Profiles - Differential Diagnosis Algorithm

Increased Cholesterol and Triglycerides 
 - Genetic Causes
Contraceptive) #Dyslipidemia
Fibrates - Gemfibrozil and Fenofibrate 
Mechanism: activates PPAR alpha
Lipid Effects:
 - Decrease TG by 30-50%
 -
used to treat dyslipidemia
Type 2 Diabetes - Screening, Diagnosis and Management Algorithm
Lifestyle  Modifications (Diet and Exercise) -> Start
risk factors (Dyslipidemia
Characteristics of Common Lipid Disorders
Polygenic hypercholesterolemia
Atherogenic dyslipidemia
 • Frequently accompanied by central obesity or diabetes
Familial hypercholesterolemia,
hypercholesterolemia Atherogenic dyslipidemia